Augmentation of the anti-lymphoma activity of an anti-CD19 immunotoxin by anti-CD20 antibody is mediated via a complement-dependent mechanism.

被引：0
|
作者：
Flavell, DJ [1 ]
Warnes, SL [1 ]
Symons, M [1 ]
Noss, A [1 ]
Flavell, SU [1 ]
机构：
[1] Univ Southampton, Sch Med, Simon Flavell Leukemia Res Unit, Southampton, Hants, England
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1475
引用
收藏
页码：342A / 342A
页数：1
相关论文
共 50 条
  • [41] Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva
    Nückel, H
    Meller, D
    Steuhl, KP
    Dührsen, U
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (04) : 258 - 262
  • [42] Ofatumumab: a novel monoclonal anti-CD20 antibody
    Lin, Thomas S.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
  • [43] Anti-CD20 antibody wows in multiple sclerosis
    Cormac Sheridan
    Nature Biotechnology, 2015, 33 : 1215 - 1216
  • [44] Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines
    Tobin, Evan
    Denardo, Gerald
    Zhang, Nan
    Epstein, Alan L.
    Liu, Cathy
    DeNardo, Sally
    LEUKEMIA & LYMPHOMA, 2007, 48 (05) : 944 - 956
  • [45] Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis
    Koh, Seung Kwon
    Kim, Hyojin
    Han, Bohwa
    Jo, Hantae
    Doh, Junsang
    Park, Jeehun
    Ha Nguyen, Minh
    Kim, Hyun-Young
    Kim, Haneul
    Lee, Seung-Hwan
    Kim, Chan Hyuk
    Cho, Duck
    BLOOD, 2025, 145 (09) : 956 - 969
  • [46] Anti-CD20 monoclonal antibody/thalidomideMyeloproliferative disorder in an elderly patient (first report with anti-CD20 monoclonal antibody): case report
    Reactions Weekly, 2001, 855 (1) : 7 - 7
  • [47] Sequential anti-CD19, anti-CD22, and anti-CD20 autologous chimeric antigen receptor T cell (CAR-T) therapies treating a child with relapsed refractory Burkitt lymphoma
    Du, Juan
    Zhang, Yonghong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Stasilojc, Grzegorz
    Felberg, Anna
    Taszner, Michal
    Urban, Aleksandra
    Ma, Shuo
    Blom, Anna
    Lundin, Jeanette
    Osterborg, Anders
    Okroj, Marcin
    MOLECULAR IMMUNOLOGY, 2019, 114 : 415 - 415
  • [49] Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies
    D Ma
    MR McDevitt
    E Barendswaard
    L Lai
    MJ Curcio
    V Pellegrini
    MW Brechbiel
    DA Scheinberg
    Leukemia, 2002, 16 : 60 - 66
  • [50] Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies
    Ma, D
    McDevitt, MR
    Barendswaard, E
    Lai, L
    Curcio, MJ
    Pellegrini, V
    Brechbiel, MW
    Scheinberg, DA
    LEUKEMIA, 2002, 16 (01) : 60 - 66
12345